Cannabidiolic Acid
The raw, unheated precursor to CBD with potent anti-nausea and anti-inflammatory properties
Cannabidiolic acid (CBDA) is the acidic precursor to CBD, present in raw, unheated cannabis and hemp. Long dismissed as an inactive precursor, CBDA has emerged as a pharmacologically active compound in its own right — with particularly potent anti-nausea effects and strong 5-HT1A receptor affinity that may exceed CBD itself.
Primary Receptors & Targets
CBDA was long considered pharmacologically inactive — a mere precursor that needed to be decarboxylated (heated) to become the "active" CBD. This view has been overturned by research demonstrating that CBDA has its own distinct and potent pharmacological activity.
CBDA's most notable mechanism is its exceptionally high affinity for 5-HT1A serotonin receptors — potentially higher than CBD itself. This strong 5-HT1A agonism is likely responsible for CBDA's potent anti-nausea effects, as 5-HT1A receptors in the dorsal raphe nucleus and brainstem play a key role in regulating nausea and vomiting.
CBDA also inhibits COX-1 and COX-2 enzymes — the same targets as NSAIDs — which explains its anti-inflammatory activity. This mechanism is distinct from CBD's anti-inflammatory pathways, suggesting CBDA and CBD may have complementary anti-inflammatory effects.
A key practical consideration: CBDA is unstable and readily converts to CBD when exposed to heat, light, or prolonged storage. Raw cannabis juice, cold-processed extracts, and refrigerated products are the primary sources of meaningful CBDA content.
CBDA is more potent than CBD for reducing nausea in animal models; particularly effective for anticipatory nausea that does not respond to conventional antiemetics.
CBDA's high 5-HT1A affinity suggests anxiolytic potential; animal studies support this, but human trials are lacking.
CBDA showed anticonvulsant effects in Dravet syndrome mouse models at lower doses than CBD.
CBDA inhibits COX-2 enzyme (similar mechanism to NSAIDs like ibuprofen) in vitro.
CBDA inhibited migration of MDA-MB-231 breast cancer cells in vitro; no human data.
Evidence levels reflect the current state of clinical and preclinical research. Preliminary evidence does not constitute medical advice. Consult a healthcare provider before using cannabinoids therapeutically.
British Journal of Pharmacology
CBDA reduced anticipatory nausea in a rat model at doses 1000x lower than CBD, suggesting dramatically higher potency for this application.
Epilepsia
CBDA reduced seizure frequency in a Dravet syndrome mouse model at lower doses than CBD, with a favorable safety profile.
Toxicology Letters
CBDA inhibited migration of highly invasive MDA-MB-231 breast cancer cells by downregulating COX-2 and ROCK1 signaling.
The recognition of CBDA's pharmacological activity has lent scientific credibility to the "raw cannabis" movement — the practice of consuming unheated cannabis (typically as fresh juice) to preserve acidic cannabinoids. Proponents argue that raw cannabis provides a distinct therapeutic profile from heated cannabis products. The science supports this to a degree: CBDA, THCA, and CBGA all have pharmacological activity that is distinct from their decarboxylated counterparts. However, raw cannabis consumption also means consuming THCA rather than THC — which has its own distinct (and non-psychoactive) pharmacological profile. The practical challenge is that acidic cannabinoids are unstable and difficult to standardize in consumer products.